Uncategorized H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT Post Content
Uncategorized Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial Post Content
Uncategorized If You Invested $500 in Baseball Cards 30 Years Ago, Would It Outperform the S&P 500? Post Content
Uncategorized Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT Post Content
Uncategorized Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating Post Content
Uncategorized Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating Post Content
Uncategorized Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma Post Content
Uncategorized How the auto industry’s players, big and small, are unlocking the power of AI Post Content
Uncategorized William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating Post Content
Uncategorized Borderlands Mexico: DP World sees big logistics opportunities across Latin America Post Content